For U.S. Residents Only

CABLIVI resources for you and your loved ones

Important and helpful information for you to download, print, or save

Download any of the PDFs below to keep important information about CABLIVI and aTTP on hand.

CABLIVI Patient Brochure

Information about CABLIVI for you and your family to download and save.

Download

CABLIVI Administration Training Guide

Information to help with the administration of CABLIVI.

Download

CABLIVI Doctor Discussion Guide

Suggested questions to ask your doctor about treatment with CABLIVI.

Download

CABLIVI Patient Solutions

Learn more about the support offered through CABLIVI Patient Solutions.

Download

The Language of aTTP

Save a list of common terms and definitions to easily reference in conversations with your healthcare team and family.

Download

CABLIVI Patient Solutions Enrollment Form

Enroll in CABLIVI Patient Solutions for specialty pharmacy services, administration training, financial assistance, and more.

Download

Patient aTTP Identification Card

It's always a good idea to be prepared in case of emergency. Let others know you have aTTP with this handy identification card.

Upload the card now

Patient aTTP Identification Card

It's always a good idea to be prepared in case of emergency. Let others know you have aTTP with this handy identification card.

Even though aTTP is rare, you are not alone

There are a number of organizations dedicated to providing information and support to people living with aTTP.

Note that the opinions expressed by the organizations above do not necessarily reflect the views of Sanofi Genzyme. Sanofi Genzyme does not maintain and is not responsible for the content of communications for the listed organizations or their websites. This is not intended to be a comprehensive list of aTTP disease support organizations. These listings do not constitute an endorsement by Sanofi Genzyme of information provided by any other organizations.

CABLIVI can help make a difference

See how CABLIVI may help you
IMPORTANT SAFETY INFORMATION
Who should not take CABLIVI?

Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.

What should I tell my healthcare team before starting CABLIVI?
Add
IMPORTANT SAFETY INFORMATION
Who should not take CABLIVI?

Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.

What should I tell my healthcare team before starting CABLIVI?

Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take.
Talk to your doctor before scheduling any surgery, medical or dental procedure.

What are the possible side effects of CABLIVI?

CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. Contact your doctor immediately if excessive bleeding or bruising occur.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants. CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.

INDICATIONS:
What is CABLIVI?

CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Please see full Prescribing Information
Instructions for Use
Sharps Medical Waste Disposal (PDF)

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.